No long-term toxicity potentially due to rituximab was observed.
未见利妥昔单抗的长期潜在毒性。
Rituximab may be effective for the treatment of CD20-positive MM.
美罗华可有效地用于治疗抗cd 20阳性毫米。
There was no increase in infections or neutropenia with rituximab.
感染和中性粒细胞减少症都没有增加。
Rituximab may be effective in controlling MCD in a subset of patients.
美罗华可有效地控制麦当劳中的一个子集的患者。
But this was the luck of the draw, for the rituximab failed to kill the cancer stem cells.
但这也许只是运气，因为rituximab没能杀灭干细胞。
Patients get rituximab through infusion into a vein (IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。
Conclusion: Combination treatment of rituximab and CHOP is effective and of little side effect.
结论：利妥昔单抗联合CHOP方案治疗DLBCL，疗效好，不良反应小。
Addition of GM-CSF did not impair tolerance to rituximab, and adverse events were rare and mild.
添加GM-CSF不减弱美罗华的耐受性，不良反应很少，并且很轻。
In the study that led to the FDA approval, most patients were refectory to bendamustine and rituximab.
在向FDA申报批准的临床研究中，大部分病人都对苯达莫司汀和利妥昔单抗耐药。
We report successful treatment with plasmapheresis and rituximab in NMO-IgG-negative relapsing disease.
我们成功的治疗报告，并与血浆中的美罗华吗啉抗体阴性复发疾病。
Conclusion the use of rituximab treatment should be closely monitored to ensure the safety of drug use.
结论使用利妥昔单抗治疗应严密监护，保证用药安全。
Rituximab, for instance, can lead to viral infections and heart problems and may be toxic to the kidneys.
以美罗华为例，就可能导致病毒感染和心脏问题，也可能有肾毒性。
The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes.
美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白cd 20。
We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
我们观察到的恶化伴随皮肤卡波西氏肉瘤，并推测这种美罗华可能加剧。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of t cells to target cancer cells have emerged.
自从FDA在1997年批准了立普妥单抗，一些新的利用T细胞的能力靶向对抗癌细胞的策略也出现了。
Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event.
先前未经治疗、而对利妥昔单抗诱导缓解有效后接受延长治疗的患者中，8年有45%患者仍无事件发生。
Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.
怀孕前应终止使用的药物包括甲氨蝶呤、来氟米特和一些生物制剂包括抗肿瘤坏死因子制剂、利妥昔单抗和阿巴西普。
Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。
Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。
Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.
在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。
Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
Objective To investigate the adverse reactions of rituximab (Rituxan and MabThera) in retrospection to provide references for safe and rational drug use clinically.
目的探讨抗肿瘤靶向药物利妥昔单抗（美罗华）不良反应的特点及规律，为临床安全、合理用药提供参考。
Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular lymphoma (FL), but single-agent rituximab is an alternative for these patients.
观察等待是无症状的晚期滤泡性淋巴瘤常用的策略，但是对于这些患者来说美罗华单药治疗也是一个选项。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
For adalimumab, etanercept and rituximab, an increase of at least 40% was seen in the number of people experiencing improved symptoms, when the drugs were compared to placebos.
阿达木单抗、依那西普和依那西普与安慰剂相对比，可以看到至少增加40%以上症状改善的病人。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
应用推荐